Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6472
-0.0291-4.30%
Post-market: 0.65480.0076+1.17%19:50 EDT
Volume:11.50M
Turnover:7.65M
Market Cap:157.27M
PE:-0.87
High:0.7060
Open:0.6759
Low:0.6400
Close:0.6763
52wk High:3.39
52wk Low:0.1611
Shares:243.00M
Float Shares:214.26M
Volume Ratio:0.22
T/O Rate:5.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-184.82%
PB:-5.42
PE(LYR):-0.36

Loading ...

Outlook Therapeutics director Yezan Munther Haddadin acquires 34,000 common shares worth $14,960

Reuters
·
May 28

Outlook Therapeutics director Kurt J. Hilzinger acquires 400,000 common shares for $176,520

Reuters
·
May 28

BUZZ-Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment

Reuters
·
May 26

Outlook Therapeutics wins appeal following FDR process for ONS-5010/Lytenava

TIPRANKS
·
May 26

Outlook Therapeutics Inc - to Resubmit Ons-5,010/Lytenava Bla in June 2026

THOMSON REUTERS
·
May 26

Outlook Therapeutics Inc - FDA Finds Substantial Evidence of Effectiveness for Lytenava in Namd

THOMSON REUTERS
·
May 26

Outlook Therapeutics says FDA grants appeal on Lyt​enava effectiveness in nAMD review

Reuters
·
May 26

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

GlobeNewswire
·
May 26

Outlook Therapeutics Inc : Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
May 18

Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Outlook Therapeutics Q2 adjusted EPS misses analyst expectations

Reuters
·
May 16

Outlook Therapeutics Q2 Adjusted EPS USD -0.16

THOMSON REUTERS
·
May 16

Outlook Therapeutics Inc - Completes FDA Dispute Resolution Meeting for Ons-5010; Decision Expected in May 2026

THOMSON REUTERS
·
May 16

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 16

BRIEF-Outlook Therapeutics Inc - Enters ATM Offering Agreement With H.C. Wainwright For Up To $100 Million - SEC Filing

Reuters
·
May 14

Outlook Therapeutics Inc - Enters Atm Offering Agreement With H.c. Wainwright for up to $100 Mln - SEC Filing

THOMSON REUTERS
·
May 14

Outlook Therapeutics inks $100 million at-the-market equity sales agreement with H.C. Wainwright

Reuters
·
May 14

Outlook Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
May 11

Outlook Therapeutics closes USD 5 million registered direct offering at USD 0.31/share

Reuters
·
Apr 24

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Dow Jones
·
Apr 24